N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
N/A N=5 Effects of Smoking State on Decision Making
Behavior
Primary: Effort Based Decision Making — 29.5; 18.3 high effort selections
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
Phase 2 N=95 Smoking, Sex Hormones, and Pregnancy
Nicotine Dependence · Contraception
Primary: Change in Smoking Urges — 5.0; 5.5 score on a scale
Phase 2 N=38 Treating Smokers With Mental Illness
Smoking Cessation · Cigarette Smoking · Schizophrenia
Primary: 7-Day Point Prevalence Abstinence — 5; 3; 4; 5 Participants
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=199 Perceptions of Cigarette Smoking in Young Adults
Smoking, Cigarette
Primary: Subjective Response to Smoking Cigarettes From the Cigarette Evaluation Scale — 4.68; 4.50 score on a scale — p=>.05
N/A N=103 Smoking Cessation in Alcoholics
Smoking Cessation · Alcohol Consumption
Primary: Number of Smoke-free Patients — 0; 3 participants — p==.111
Phase 2 N=236 Improving Smoking Cessation Outcomes in Heavy Drinkers - 1
Tobacco Use Disorder
Primary: Smoking Abstinence at 26 Weeks — 21; 22 participants — p=>.05
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=184 Brain Nicotine Receptor Density in Veteran Smokers
Positron Emission Tomography
Primary: PET Scan, Rating Scales — 7.1; 8.6; 7.9; 8.0 Vt/fp or mL/cm3
N/A N=40 Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
Smoking Behaviors
Primary: Number of Puffs Taken (Video-scored Smoking Behavior Outcome 1) — 15.8; 16.7; 19.1; 19.6 puffs
N/A N=294 Smoking Cessation Using Motivational Therapy and Varenicline
Smoking · HIV Infections
Primary: To Determine the Safety of Varenicline in PLWH Who Smoke — 13; 38; 3; 4 Participants
Phase 2 N=151 Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk
Tobacco Use Cessation · Alcohol-related Disorders
Primary: Smoking Abstinence — 20; 1 participants — p=<.01
N/A N=60 Smoking Topography and Harm Exposure in Menthol Cigarettes
Cigarette Smoking Toxicity
Primary: Smoking Topography- Puff Volume — 518; 661; 650; 620 mL
N/A N=116 Coping Skills Treatment for Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Biochemically Verified Smoking Abstinence — 11; 12 Participants
N/A N=49 Smoking Cessation Intervention for Women Living With HIV
AIDS/HIV
Primary: Number of Participants With Abstinence — 8; 1 Participants — p=< 0.05
N/A N=30 Sugars in Cigarettes
Tobacco Use
Primary: Impact of Cigarette Sugar Content on Product Satisfaction. — 4.09; 3.89; 3.92; 4.39 units on a scale
N/A N=150 Methods Project 4: Clinical Trial
Smoker
Primary: Smoke-free Days — 14.5; 0; 0 days
Phase 2 N=746 Gradual vs. Abrupt Cessation Treatment for Smoking
Smoking Cessation
Primary: Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement — 12; 20; 7 participants — p=0.30
Phase 2 N=24 Varenicline and Smoking Cessation in Schizophrenia
Schizophrenia · Smoking Cessation
Primary: Smoking Abstinence - Serum/Urine Measurements — 198.67; 207; 213.8; 22.57 ng/mL — p=>0.05
N/A N=22 Comparative Abuse Liability Among African American and White Smokers
Tobacco Use Disorder
Primary: Nicotine Delivery — 14.13; 6.79; 9.15 ng/mL — p=0.002
N/A N=300 Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers
Tobacco Use Disorder
Primary: Quit Rate — 13; 23 Participants
Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
N/A N=80 Low Nicotine Cigarettes Plus Electronic Cigarettes
Tobacco Dependence
Primary: Urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) — 505.6; 459.1; 373.3; 180.5 pg/mg creatinine — p=0.017
N/A N=25 Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
Healthy Volunteers
Primary: Nicotine Cmax — 13.00; 12.97; 6.00; 6.87 ng/mL
Phase 3 N=157 Varenicline for Adolescent Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment — 4; 4 Participants